![Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/eeaa5e6c-b7fd-45c9-932b-7ed90a186cb0/jcpt12404-fig-0003-m.jpg)
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![Design of a Stable Cyclic Peptide Analgesic Derived from Sunflower Seeds that Targets the κ-Opioid Receptor for the Treatment of Chronic Abdominal Pain | Journal of Medicinal Chemistry Design of a Stable Cyclic Peptide Analgesic Derived from Sunflower Seeds that Targets the κ-Opioid Receptor for the Treatment of Chronic Abdominal Pain | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.1c00158/asset/images/large/jm1c00158_0008.jpeg)
Design of a Stable Cyclic Peptide Analgesic Derived from Sunflower Seeds that Targets the κ-Opioid Receptor for the Treatment of Chronic Abdominal Pain | Journal of Medicinal Chemistry
![Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ff659c0a-df99-4a5e-8df9-c1e1925ea7d0/jcpt12404-fig-0001-m.jpg)
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects](https://pub.mdpi-res.com/molecules/molecules-28-00346/article_deploy/html/images/molecules-28-00346-g007.png?1672561695)
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
![Role of kappa‐opioid and mu‐opioid receptors in pruritus: Peripheral and central itch circuits - Kim - 2022 - Experimental Dermatology - Wiley Online Library Role of kappa‐opioid and mu‐opioid receptors in pruritus: Peripheral and central itch circuits - Kim - 2022 - Experimental Dermatology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/a99fbbbf-3277-4e82-886b-4b0017b91684/exd14669-fig-0002-m.jpg)
Role of kappa‐opioid and mu‐opioid receptors in pruritus: Peripheral and central itch circuits - Kim - 2022 - Experimental Dermatology - Wiley Online Library
Design of a Stable Cyclic Peptide Analgesic Derived from Sunflower Seeds that Targets the κ-Opioid Receptor for the Treatment of Chronic Abdominal Pain | Journal of Medicinal Chemistry
![Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/72b7cca4-2c69-4c1d-9ca9-f017f875ba0b/jcpt12404-fig-0002-m.jpg)
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus | National Eczema Association Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus | National Eczema Association](https://nationaleczema.org/wp-content/uploads/2021/04/Website_NewTreatments_PressReleases_Cara.png)
Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus | National Eczema Association
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-ga1.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-gr6.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-gr5.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/375/2/332/F3.medium.gif)
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
![Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/375/2/332/F2.medium.gif)
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
![Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink](https://media.springernature.com/lw685/springer-static/image/chp%3A10.1007%2F164_2020_431/MediaObjects/500126_1_En_431_Fig1_HTML.png)